Staff

Barbara Engelhardt, PhD, builds machine-learning models and statistical tools to make use of data (scientific experiments, longitudinal studies, clinical trials, and hospital records) and find ways to better understand, and even prevent, disease. She is now joining Gladstone Institutes as a senior investigator. Engelhardt is also a full professor at Princeton University, on leave this … Read more

The National Institutes of Health (NIH) is providing approximately $185 million over five years to the Impact of Genomic Variation on Function (IGVF) consortium, initiated and funded by NIH’s National Human Genome Research Institute (NHGRI). NHGRI will fund 25 awards across 30 U.S. research sites. IGVF consortium investigators will work to understand how genomic variation … Read more

The word “army” typically conjures up images of ground warfare. As the military’s DARPA program proves, some key innovations we enjoy today have emerged from military efforts. Here is an example of the U.S. Army aiming to deliver a way to use gene editing to convert waste materials into something useful. As part of an … Read more

Proteins are the workhorses of the cell. Mapping the precise shapes of the most important of these workhorses helps to unlock their life-supporting functions or, in the case of disease, potential for dysfunction. While the amino acid sequence of a protein provides the basis for its 3D structure, deducing the atom-by-atom map from principles of … Read more

For years, the foundations of cancer treatment were surgery, chemotherapy, and radiation therapy. Over the last two decades, targeted therapies like imatinib (Gleevec®)  and trastuzumab (Herceptin®) —drugs that target cancer cells by homing in on specific molecular changes seen primarily in those cells—have also cemented themselves as standard treatments for many cancers. But over the past several years, immunotherapy—therapies that enlist and … Read more

There is a fundamental problem at the heart of all cancers: cells that won’t stop dividing, or hyperproliferation, along with genomic instability. This runaway growth is what forms a tumor, and the abnormal cellular processes that drive this growth also thwarts therapies that target cancer cells. Despite more than six decades of research into the … Read more